NCT01670084View on ClinicalTrials.gov

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2017

Conditions
B-cell Adult Acute Lymphoblastic LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaUntreated Adult Acute Lymphoblastic Leukemia
Interventions
DRUG

nilotinib

Given PO

BIOLOGICAL

rituximab

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

methotrexate

Given IV or IT

DRUG

cytarabine

Given IV or IT

DRUG

prednisone

Given PO

DRUG

mesna

Given IV

DRUG

dexamethasone

Given IV or PO

DRUG

leucovorin calcium

Given IV

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER